Average more than 10 years! How big is the gap between domestic insulin manufacturers and the research and development of giants Noor and Nord?

Guide: Some drugs, the gap between inside and outside is not generally large! The gap in research and development strength between pharmaceutical companies mainly depends on products, and the gap between products mainly depends on the period of patent protection listed and its research and development pipeline.
I, No and NOD has listed product patent term No and NORD 2019 report disclosed the patent term of listed products in four countries around the world as follows: translation is as follows: 2, No and NORD R and D pipeline Noel and NORD 2019 report made a detailed disclosure of its research and development pipeline, see figure below: translation is as follows: Noor and NORD research and development pipeline is basically First-in-class drugs.
, gap assessment 1, listed drugs (the same product was first approved for market time difference) - Mendong insulin: a difference of 21 years.
and Nordmendon insulin were listed in Europe in 1999, in the United States in 2000, in China in 2002, and in 2020 local company Gan Li Pharmaceutical Mendong.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
consider clinical trials and product registration for 5 years.
Liraglutide: More than 13 years apart (local companies are expected to be listed as early as 2022) listed in Europe in 2009 and approved by the FDA in early 2010, the patent has lapsed in China.
there are currently 12 enterprises in China to carry out clinical or reported production, of which East China Pharmaceuticals and Thua Dongbao will probably be the earliest listing.
Degu insulin: a difference of more than 11 years (local companies are expected to list in 2026) in 2015 by the U.S. FDA approved listing, in 2017 in China, patent protection period until 2024.
At present, China has Haizheng Pharmaceuticals, Four Rings Pharmaceuticals (Jilin Jinsheng United Chongqing Pakin), Federal Pharmaceuticals, Zheng Datianqing, Chongqing Yan'an Biological 5 enterprises apply for or approve clinical, East China Medicine, Twain Dongbao 2 enterprises are in the preclinical research stage.
consider clinical trials and product registration for 5 years.
no and Jia (Degu Mendong double insulin) Ryzodeg injections: a difference of more than 16 years (local companies are expected to be listed in 2028) first listed in 2012, listed in China in 2019, China patent protection period until 2024.
media has now revealed that only one federal pharmaceutical company is conducting preclinical studies.
- Degu insulin compound preparation (Degu insulin liraglutide injection): a difference of more than 14 years (local companies are expected to be listed in 2028) was approved by Europe in 2014, approved by the FDA in 2015, and is currently in China for Phase III clinical treatment.
china's patent protection period until 2024.
media has now revealed that only one federal pharmaceutical company is conducting preclinical studies.
2, research and development pipeline products (average difference of more than 10 years) 3, the actual research and development gap - listed drugs (the same product was first approved for the market time difference, 11-21 years) and research and development pipeline products (average difference of 10 years) - 21 years - 31 years.